Detection of fumarate-glutathione adducts in the portal vein blood of rats: Evidence for rapid dimethylfumarate metabolism

Archives of Dermatological Research

Volumn 305, Issue 5, 2013, Pages 447-451

  Dibbert, Stefan ^a   Clement, Bernd ^b   Skak Nielsen, Tine ^c   Mrowietz, Ulrich ^a   Rostami Yazdi, Martin ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c LEO PHARMA A S   (Denmark)

Author keywords

Anti inflammatory drugs; Dimethylfumarate; Fumaric acid esters; Glutathione; Multiple sclerosis; Portal vein; Psoriasis

Indexed keywords

(1,2 DIMETHOXYCARBONYLETHYL)GLUTATHIONE; ACETYLCYSTEINE; DIMETHYLFUMARATE; FUMADERM; FUMARIC ACID; GLUTATHIONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; METABOLITE; MULTIPLE SCLEROSIS; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; PSORIASIS; RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DERMATOLOGIC AGENTS; FUMARATES; GLUTATHIONE; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; PORTAL VEIN; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84879549754     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-013-1332-y     Document Type: Article

References (16)

1. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087-1097
2. Frycák P, Zdráhal Z, Ulrichová J, Wiegrebe W, Lemr K (2005) Evidence of covalent interaction of fumaric acid esters with sulfhydryl groups in peptides. J Mass Spectrom 40:1309-1318
3. Gerdes S, Shakery K, Mrowietz U (2007) Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol 156:838-842
4. Ghoreschi K, Brück J, Kellerer C, Deng C, Peng H, Rothfuss O et al (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208:2291-2301
5. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098-1107
6. Höxtermann S, Nuchel C, Altmeyer P (1998) Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 196:223-230
7. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V et al (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372:1463-1472
8. Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC et al (2004) Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol 58:429-432
9. Mrowietz U, Christophers E, Altmeyer P (1999) Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 141:424-429
10. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C (1998) Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci USA 95:3071-3076
11. Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T (2009) Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis - a retrospective study (FUTURE). J Dtsch Dermatol Ges 7:603-611
12. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U (2009) Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol 129:231-234
13. Rostami-Yazdi M, Clement B, Mrowietz U (2010) Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res 302:531-538
14. Schmidt TJ, Ak M, Mrowietz U (2007) Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-l-cysteine-preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem 15:333-342
15. Treumer F, Zhu K, Gläser R, Mrowietz U (2003) Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 121:1383-1388
16. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P (2003) Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 24:259-273